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unctions of bone morphogenetic proteins (BMPs) are
initiated by signaling through speciﬁc type I and type II
serine/threonine kinase receptors. In previous studies,
we have demonstrated that the type IB BMP receptor
(BMPR-IB) plays an essential and speciﬁc role in osteoblast
commitment and differentiation. To determine the role of
BMP receptor signaling in bone formation in vivo, we
generated transgenic mice, which express a truncated
dominant-negative BMPR-IB targeted to osteoblasts using
the type I collagen promoter. The mice are viable and fertile.
Tissue-speciﬁc expression of the truncated BMPR-IB was
demonstrated. Characterization of the phenotype of these
transgenic mice showed impairment of postnatal bone
F
 
formation in 1-mo-old homozygous transgenic mice. Bone
mineral density, bone volume, and bone formation rates
were severely reduced, but osteoblast and osteoclast numbers
were not signiﬁcantly changed in the transgenic mice. To
determine whether osteoblast differentiation is impaired,
we used primary osteoblasts isolated from the transgenic
mice and showed that BMP signaling is blocked and
BMP2-induced mineralized bone matrix formation was
inhibited. These studies show the effects of alterations in
BMP receptor function targeted to the osteoblast lineage
and demonstrate a necessary role of BMP receptor signaling
in postnatal bone growth and bone formation in vivo.
 
Introduction
 
Bone morphogenetic proteins (BMPs)* are multifunctional
growth factors that mediate a variety of biological functions,
including osteoblast differentiation and bone formation
(Urist, 1965; Wozney et al., 1988; Wozney 1992). BMPs
signal through serine/threonine kinase receptors composed
of type I and type II components. Three subtypes of type I
receptors, which mediate BMP signaling, have been identified,
including the types IA and IB BMP receptors and the type
IA activin receptor (Koenig et al., 1994; ten Dijke et al.,
1994; Yamaji et al., 1994; Macias-Silva et al., 1998). These
receptors are expressed differentially in various tissues. For
example, the type IA BMP receptor is highly expressed
throughout mouse development and in adult tissues (Dewulf
et al., 1995), whereas the type IB BMP receptor is expressed
in mesenchymal precartilage condensations during mouse
development and in chondrocytes and osteoblasts in adult
mice (Yamaji et al., 1994; Dewulf et al., 1995; Ishidou et al.,
1995). Relative levels of expression of these receptors and
their timing of expression may be critical for determination
of the appropriate biological response.
To examine the role of type I BMP receptor in osteoblast
differentiation, we have previously stably expressed truncated
dominant-negative (kinase domain deletion) and constitu-
tively active types IA and IB BMP receptors in a clonal osteo-
blast precursor cell line, 2T3. Overexpression of the truncated
type IB BMP receptor completely blocked BMP2-induced
mineralized bone matrix formation and inhibited expression
of genes that are associated with osteoblast differentiation,
such as alkaline phosphatase, osteocalcin, and the bone specific
transcription factor, Runx2/Cbfa1 (Chen et al., 1998). 2T3
cells expressing the truncated BMPR-IB were respecified to
differentiate into mature adipocytes. Consistent with these
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results, overexpression of the constitutively active BMPR-IB
in 2T3 cells induced BMP-independent mineralized bone
matrix formation (Chen et al., 1998). These results demon-
strate that BMPR-IB plays an important and specific role in
osteoblast commitment and differentiation in vitro.
To determine the role of BMP receptors in bone forma-
tion in vivo, we have now generated transgenic mice, which
overexpress the truncated BMPR-IB transgene. Expression
of truncated BMPR-IB was targeted to osteoblasts by using
the type I collagen promoter, which is specific for the osteo-
blast lineage. Characterization of the phenotypes of these
transgenic mice revealed impairment in BMP receptor sig-
naling as well as bone growth and bone formation in ho-
mozygous transgenic mice. Our results show that BMPs and
BMP receptor signaling are necessary components for osteo-
blast differentiation and postnatal bone formation in vivo.
 
Results
 
Generation of the truncated BMPR-IB transgenic 
mouse lines
 
We first constructed two truncated, HA-tagged BMPR-IB
transgenes, one driven by the type I collagen enhancer/basal
promoter (0.7 kb) and the other by the 2.3-kb type I collagen
promoter. These two promoters have been shown to direct
bone-specific expression of reporter genes in vivo (Rossert et
al., 1995, 1996). Using these type I collagen promoters to di-
rect expression of the truncated BMPR-IB transgene, we gen-
erated two types of transgenic mice. Three founder trans-
genic mice for type I collagen enhancer/basal promoter (0.7
kb) (tg[Col-0.7]) and one founder mouse for 2.3-kb type I
collagen promoter (tg[Col-2.3]) were generated and analyzed
in these studies. One female founder mouse that contains
high copy numbers of Col1a1(0.7)-trBMPR-IB transgene
was very small and did not breed. This may be due to the de-
fects in the female reproductive organs (Yi et al., 2001). The
other three founder mice were bred to wild-type nontrans-
genic CB6F1 mice to establish the lines of mice. Heterozy-
gous mice were then interbred to produce homozygous mice.
Transgenic mice were genotyped by Southern blot analysis
and by PCR and the genotype of homozygous mice was fur-
ther confirmed by back breeding. The PCR primers for de-
tection of the truncated BMPR-IB transgene have been de-
scribed previously (Chen et al., 1998). Both heterozygous
and homozygous mice for two types of transgenic mice were
viable and fertile and survived into adulthood. The pheno-
types of all these transgenic mouse lines are similar.
 
Tissue-specific expression of the truncated 
BMPR-IB transgene
 
We have examined expression of truncated BMPR-IB in ho-
mozygous transgenic mice by RT-PCR as described (Chen et
al., 1998). Total RNA was extracted from different tissues in-
cluding bones of 1-mo-old transgenic mice and from bones of
2-mo-old transgenic mice. Three different lines of mice were
analyzed and expression levels of the truncated BMPR-IB
transgene were determined and compared with those of endog-
enous BMPR-IB. Truncated BMPR-IB mRNA was strongly
expressed in bone tissues, and in contrast, only a weak expres-
sion was detectable in skin and muscle of 1-mo-old transgenic
mice (Fig. 1 A, top, tg[Col-0.7] and bottom, tg[Col-2.3]). In
all other tissues, including brain, liver, heart, lung, and kidney,
expression of truncated BMPR-IB transgene was undetectable
(Fig. 1 A). Expression of the truncated BMPR-IB transgene
was stable, as strong expression of the transgene was observed
in bones in both 1- and 2-mo-old transgenic mice (Fig. 1 B).
We also determined expression of the truncated BMPR-IB in
bones by Western blot analysis. Cell lysates were extracted
from calvariae of wild-type and tg(Col-2.3) transgenic mice.
Immunoblotting using an anti-HA antibody demonstrated ex-
pression of the truncated BMPR-IB protein in bones of trans-
genic mice, but not in those of wild-type mice (Fig. 1 C).
 
Changes in bone development in truncated BMPR-IB 
transgenic mice
 
To examine changes in bone development, we analyzed
three litters of 18.5-dpc embryos of tg(Col-2.3) transgenic
mice by whole-embryo Alizarin red and Alcian blue staining.
Bone development was normal in both wild-type and het-
erozygous embryos. In homozygous embryos, the sizes of
Figure 1. Tissue-specific expression 
of the truncated BMPR-IB transgene. 
(A) mRNA expression of the truncated 
BMPR-IB (Tr-IB) transgene in 1-mo-old 
transgenic mice. Bone and other tissues 
were collected from 1-mo-old tg(Col-0.7) 
and tg(Col-2.3) homozygous transgenic 
mice. The truncated BMPR-IB transgene 
was amplified using the primers 
described previously (Chen et al., 1998). 
(B) mRNA expression of truncated (Tr-IB) 
and endogenous (En-IB) BMPR-IB in 
bone tissues in 1- and 2-mo-old 
tg(Col-0.7) and tg(Col-2.3) transgenic 
mice. (C) Protein expression of the truncated BMPR-IB (Tr-IB) 
transgene in bones. Calvarial bones were collected from 1-mo-old 
wild-type and tg(Col-2.3) transgenic mice. The cell lysates were 
extracted using lysis buffer and then sonicated on ice. Western 
blot was performed using anti-HA antibody. 
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embryos were smaller than those of wild-type littermates.
Mineralization of calvarial bones, including frontal, parietal
and interparietal bones, was delayed in these homozygous
embryos (Fig. 2, A and B). In contrast to the phenotypes ob-
served in Runx2/Cbfa1 heterozygous knockout mice, clavi-
cle bones developed normally in tg(Col-2.3) homozygous
embryos (Fig. 2, A and C). In 18.5–d postcoitum (dpc)
wild-type embryos, the ossification centers were formed in
distal and proximal phalangeal bones. In contrast, no ossifi-
cation center was formed in these bones in the transgenic lit-
Figure 2. Alizarin red and Alcian blue staining of transgenic 
embryos. 18.5-dpc mouse embryos were killed and processed for 
Alizarin red and Alcian blue staining. The sizes of tg(Col-2.3) 
homozygous transgenic embryos were smaller than those of 
wild-type embryos. (A and B) Delayed ossification of frontal (F), 
parietal (P), interparietal (I), and supraoccipital (S) bones were noted 
in homozygous transgenic embryos and indicated by arrows 
(A and B). The wild-type embryos showed normal mineralization in 
calvarial bones. The clavicle (C) developed normally in both 
wild-type and homozygous transgenic embryos (A and C). 
(C and D) The formation of ossification centers (OCs) of distal and 
proximal phalangeal bones were observed in wild-type embryos but 
not in homozygous transgenic embryos (D, arrows). 
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termates (Fig. 2, C and D). This is consistent with the over-
all delay in mineralization in transgenic mice.
 
Impairment of bone growth and reduction of bone 
mineral density in truncated BMPR-IB transgenic mice
 
To determine whether bone growth is impaired in the trans-
genic mice, we measured body weight and analyzed changes
in bone growth and bone mineral density (BMD) in 1-mo-
old wild-type and three lines of homozygous mice by radio-
graphic analysis and by bone densitometry. The average
body weights of tg(Col-0.7) and tg(Col-2.3) mice were sig-
nificantly and consistently less (12 and 22%, respectively)
than those of the wild-type littermates throughout their life
(Fig. 3 A). Radiographic analysis confirmed the reduction in
size and also showed that bone densities in the hind limbs in
tg(Col-2.3) homozygous mice were less than those of wild-
type mice (Fig. 3, B and C).
To determine changes in bone formation during bone
modeling and remodeling phases in the transgenic mice,
we first analyzed temporal changes in BMD in wild-type
CB6F1 mice using PIXImus bone densitometer. In wild-
type CB6F1 mice, BMD increased with age and plateaued
after 10 wk (Fig. 4), suggesting that bone modeling contin-
ues until peak bone mass is achieved at 10 wk of age in
CB6F1 mice. Bone remodeling starts thereafter. BMDs
in three litters of transgenic mice and age-matched wild-
type mice were then compared. BMD in tg(Col-0.7) and
tg(Col-2.3) transgenic mice was reduced 5–9% and 8–13%,
respectively relative to sex and age-matched wild-type mice
after adjusting for body weight (Fig. 4, A and B). These
results demonstrate that BMP signaling through BMP IB
receptor and its interacting components play an important
role in bone formation and maintaining BMD in adult
animals.
Figure 3. Impairment of bone growth in 
truncated BMPR-IB transgenic mice. (A) The 
comparison of the body weight between 1-mo-old 
wild-type and homozygous transgenic mice. Three 
litters of wild-type and transgenic mice were 
pooled. The body weights of tg(Col-0.7) and 
tg(Col-2.3) transgenic mice are 12 and 22% lower 
compared with age-matched wild-type mice. 
(B and C) x-ray analysis of tg(Col-2.3) transgenic 
mouse. Radiographs of 1-mo-old wild-type (left) 
and homozygous transgenic mouse (right) is shown 
in (B). Note the significantly smaller size of the 
homozygous transgenic mouse was compared 
with its wild-type littermate. The density of the 
long bones was also decreased in the transgenic 
mouse as indicated by arrows (C).
Figure 4. Temporal changes in BMD in wild-type and transgenic mice. The BMDs in distal femora and proximal tibiae were monitored 
using PIXImus bone densitometer in 6-, 8-, 10-, and 12-wk-old wild-type and transgenic mice. Significant reduction in BMD in tg(Col-0.7) 
(A) and tg(Col-2.3) (B) homozygous transgenic mice was observed compared with the sex- and age-matched wild-type mice. The body 
weight was adjusted after measurements. *P   0.05, two-way analysis of variance followed by Dunnett’s test. 
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Osteopenia in truncated BMPR-IB transgenic mice
 
Differences in bone formation between transgenic and wild-
type mice were confirmed by bone histomorphometric anal-
yses. Comparison of trabecular bone volumes in wild-type
and transgenic mice revealed a 26% reduction in bone vol-
ume in 1-mo-old tg(Col-0.7) mice and 34% reduction in
bone volume in 1-mo-old tg(Col-2.3) mice (Fig. 5, A and
B). Because trabecular bone volume represents the percent-
age of bone in a well-defined area of bone marrow cavity,
these results suggest that homozygous transgenic mice de-
velop osteopenia postnatally due to disruption in BMP re-
ceptor signaling. To investigate whether dynamic changes in
bone formation in transgenic mice, we measured bone for-
mation rates (BFRs) and found that these were reduced by
58% in tg(Col-2.3) mice (Fig. 5, C and D).
BMP-2 has been shown to stimulate osteoblast proliferation
and differentiation in vitro. It has been reported that the pro-
liferation of the prechondrogenic cells was reduced in BMPR-
IB knockout mice (Yi et al., 2000). To analyze histological
changes in bone and changes in osteoblast numbers in trans-
genic mice, we stained bone sections with hematoxylin and
eosin. Trabecular bones were reduced in transgenic mice but
cortical bones were similar to the wild-type mice (Fig. 5
E). Osteoblast numbers were enumerated in wild-type and
Figure 5. Histological and histomorphometric 
analyses of proximal tibia of 1-mo-old wild-type 
and transgenic mice. (A and B) von Kossa–stained 
tibiae were used to measure the trabecular bone 
volume (BV) in the entire area of the bone marrow 
cavity 1–3 mm from the growth plates and 
expressed as a percentage of total tissue volume 
(TV) (n   10). The bone volumes in tg(Col-0.7) 
and tg(Col-2.3) transgenic mice were significantly 
reduced compared with those of wild-type mice. 
*P   0.05, t test. (C and D) The BFRs/BS were 
measured in the same area and expressed as 
 m
3/ m
2/d (n   10). The BFRs were significantly 
reduced in tg(Col-2.3) transgenic mice compared 
with the wild-type mice. *P   0.05, t test. (E and F) 
Bone sections were stained with Hematoxylin 
and Eosin (E) (C: cortical bone; T: trabecular 
bone) and the numbers of osteoblasts in wild-type 
and tg(Col-2.3) transgenic mice were counted in 
hematoxylin and eosin–stained sections (F). 
Osteoblasts in the same area were also stained for 
ALP activity (G and H). (I and J) Tibiae were 
stained with Goldner method and osteoid thickness 
in the same area was measured. In tg(Col-2.3) 
transgenic mice, the osteoid thickness was 
significantly reduced compared with that of 
wild-type mice (I and J). *P   0.05, t test. 
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Figure 6. Impairment of periosteal 
bone formation in truncated BMPR-IB 
transgenic mice. (A and B) The 
responsiveness of tg(Col-2.3)
homozygous transgenic mice to BMP-2. 
BMP-2 (20  g/kg/d, daily for 5 d) in 20 
 l PBS containing 0.1% BSA were 
injected into mice subcutaneously, 
adjacent to the calvarial bones. Significant 
amounts of new woven bone, indicated 
by red arrows and a black arrow head, 
were formed on the periosteal surface of 
calvariae in wild-type mice receiving 
BMP-2, but not in homozygous transgenic 
mice receiving BMP-2. The existing 
bones were indicated by a black arrow 
(A). Similarly, BMP-2 (20  g/kg/d,  5d) 
was administered subcutaneously and 
Calcein and Alizarin red were injected 7 
and 2 d before the animals were killed. 
The new bone formation during the two 
fluorochrome injection (5-d period) was 
observed in wild-type mice (indicated 
by white arrows and a black arrowhead) 
but not in tg(Col-2.3) mice (B). (C) Effects 
of TGF  on periosteal bone formation. 
TGF  (20  g/kg/d, daily for 5 d) was 
injected subcutaneously over calvariae. 
Significant amounts of new woven bone, 
indicated by red arrows and a black 
arrowhead, were formed on the 
periosteal surface of calvariae in wild-type 
and homozygous transgenic mice. 
(D and E) In vitro bone formation assay. 
Calvariae were isolated from 4-d-old 
wild-type and tg(Col-2.3) mice and 
cultured for 7 d in BGJ medium. At the 
end of the incubation, calvariae were fixed 
and processed for histomorphometric 
analyses. Osteoblasts on the BS were 
indicated by red arrows and existing 
bones were indicated by yellow arrows 
(D). The thickness of calvariae were 
measured and presented in (E). 
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tg(Col-2.3) mice and a slight reduction in osteoblast numbers
were found in transgenic mice compared with their wild-type
littermates (Fig. 5 F). To examine osteoblast function, we
stained osteoblasts cytochemically for alkaline phosphatase
(ALP) activity. Osteoblasts on the surfaces of trabecular bone,
endosteum, and periosteum were stained with ALP in both
wild-type and transgenic mice (Fig. 5, G and H)
Because BMP-2 has also recently been shown to stimulate
osteoclast differentiation and survival in vitro (Itoh et al.,
2001), in the present studies, we also stained sections for tar-
trate-resistant acid phosphatase activity, which delineates os-
teoclasts, and compared osteoclast numbers in wild-type and
tg(Col-2.3) mice. We found that there was no significant
difference in osteoclast numbers between wild-type and
transgenic mice (unpublished data).
To examine changes in matrix mineralization in trans-
genic mice, we also measured osteoid thickness in transgenic
mice. Using plastic-embedded sections of proximal tibiae
from 1-mo-old wild-type and tg(Col-2.3) mice stained by
Goldner method, we found that there was a significant de-
crease (31%) in osteoid thickness in the transgenic mice
compared with wild-type littermates (Fig. 5, I and J).
 
Impairment of periosteal bone formation in truncated 
BMPR-IB transgenic mice
 
We analyzed periosteal bone formation of calvariae in 1-mo-
old transgenic mice. BMP-2 was injected subcutaneously (20
 
 
 
g/kg/d; daily for 5 d) over calvariae (
 
n
 
 
 
 
 
 5). Administration
of BMP-2 induced new bone formation over calvariae of wild-
type mice but not those of homozygous tg(Col-2.3) mice (Fig.
6 A). In heterozygous mice, BMP-2 induced new bone forma-
tion on calvariae but the effects were 30–40% less in compari-
son to their wild-type littermates (unpublished data). These
results strongly imply that responses of the mice are related to
the levels of the transgene. To further confirm the de novo
bone formation over the surface of calvariae, we labeled calva-
rial bones by injecting Calcein and Alizarin red after BMP-2
treatment. A significant new bone formation indicated by
Calcein and Alizarin red labeling was observed in wild-type
but not in homozygous tg(Col-2.3) mice (Fig. 6 B).
To further examine the specificity of the blockage of BMP
receptor signaling in transgenic mice, TGF
 
 
 
 (20 
 
 
 
g/kg/d;
daily for 5 d), a known inducer of bone formation in this as-
say (Marcelli et al., 1990), was injected subcutaneously over
calvariae of 1-mo-old wild-type and transgenic mice. TGF
 
 
 
induced extensive new bone formation in both wild-type
and tg(Col-2.3) homozygous transgenic mice (Fig. 6 C).
These results indicate that BMP signaling is specifically
blocked in truncated BMPR-IB–expressing transgenic mice.
Although BMP-2 failed to induce new bone formation in
homozygous transgenic mice in vivo, it was still unclear
whether normal bone formation was impaired in these trans-
genic mice since de novo bone formation is not observed on
calvariae of both wild-type and homozygous transgenic mice
without exogenous BMP-2 treatment. To assess the role of
endogenous BMP signaling in normal bone formation, cal-
variae were isolated from wild-type and tg(Col-2.3) mice
and cultured for 7 d (Traianedes et al., 1998), after which
they were fixed and processed for histomorphometric analy-
ses. Thickness of calvariae from transgenic mice was found
to be 37% less than those of wild-type mice (Fig. 6, D and
E). Because newly formed bones can be identified on calva-
riae of transgenic mice, these results suggest that BMP sig-
naling is a necessary growth signal for normal bone for-
mation but may not be obligatory. Other bone growth
regulatory factors may compensate the loss of BMP signaling
or complete blockage of BMP receptor signaling may not
have been achieved in these viable mouse lines.
 
Blockage of BMP signaling in truncated BMPR-IB 
transgenic mice
 
To examine BMP signaling in osteoblasts, primary osteo-
blasts were isolated from calvariae of 3-d-old wild-type and
transgenic mice by trypsin/collagenase sequential digestion,
transfected with Flag-Smad1 cDNA construct, and the nu-
clear translocation of Smad1 was determined by the immu-
nofluorescence staining. Smad1 nuclear translocation was
clearly inhibited in cells from transgenic mice (Fig. 7 A).
These results were also supported by a reporter assay using a
9 
 
  
 
SBE-OC-pGL3 reporter gene, containing nine copies
Figure 7. Blockage of BMP signaling in 
truncated BMPR-IB transgenic mice. 
(A) Flag-Smad1 expression plasmid was 
transfected in primary osteoblasts isolated 
from calvariae of wild-type and tg(Col-2.3) 
mice in the absence or presence of BMP-2 
(50 ng/ml). The experiment of nuclear 
localization of Smad1 was performed by 
immunofluorescence staining. Nuclear 
translocation of Flag-Smad1 was 
observed in osteoblasts from wild-type 
mice after BMP-2 treatment but not in 
osteoblasts from transgenic mice with 
BMP-2 treatment (50 ng/ml). The DAPI 
nuclear staining was performed as 
control in this experiment. (B) 9   SBE-
OC-pGL3 reporter and  -gal control 
plasmids were cotransfected in primary osteoblasts isolated from calvariae of wild-type and transgenic mice. The luciferase activity was 
measured by luciferase assay kit using Luminometer. BMP-2 induced luciferase activity in a dose-dependent manner in osteoblasts from 
wild-type mice. In transgenic mice, BMP-2–induced luciferase activity was significantly inhibited. *P   0.05, two-way analysis of 
variance followed by Dunnett’s test. 
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of a Smad1 response element (Kusanagi et al., 2000) linked
to the osteocalcin basal promoter. Addition of BMP-2 stim-
ulated luciferase activity of this reporter gene in a dose-
dependent manner in osteoblasts from wild-type mice. In
contrast, low concentration of BMP-2 (25 and 50 ng/ml)
failed to activate the reporter gene in cells isolated from
tg(Col-2.3) mice, although high concentrations of BMP-2
(100 and 200 ng/ml) retained some activity in this regard
(Fig. 7 B). These results confirm disruption of BMP signal-
ing in osteoblasts of transgenic mice.
 
Impairment of osteoblast differentiation in truncated 
BMPR-IB transgenic mice
 
To further analyze whether osteoblast differentiation capac-
ity is impaired in the transgenic mice, primary osteoblasts
isolated from calvariae of wild-type and tg(Col-2.3) ho-
mozygous transgenic mice were cultured in an osteoblast
differentiation medium containing glycerophosphate and
ascorbic acid. As we had previously reported, in these pro-
longed cultures, bone matrix deposition and mineralization
was induced by BMP-2 after 10-d incubation in cultures of
osteoblasts isolated from wild-type mice (Chen et al., 1998).
In contrast, there was no obvious mineralized bone matrix
formation in cultures of osteoblasts isolated from homozy-
gous transgenic mice under the same conditions even in the
presence of BMP-2 (50 ng/ml) (Fig. 8 A).
Expression of osteoblast marker genes were also analyzed
in tg(Col-2.3) mice. Runx2/Cbfa1 and osteocalcin were de-
tected in the long bones of 1-mo-old wild-type mice by RT-
PCR. In homozygous transgenic mice, expression of Runx2/
Cbfa1 and osteocalcin were significantly reduced compared
with that in wild-type mice (Fig. 8 B), suggesting that inhi-
bition of bone formation in transgenic mice in vivo is partly
due to impairment of osteoblast differentiation.
 
Discussion
 
BMPs were originally identified from bone matrix using an
ectopic bone formation assay (Urist, 1965; Wozney et al.,
1988). Careful examination of the ectopic bone formation
model indicates that it closely mimics the normal processes
of endochondral bone formation (Wozney, 1992). The
function of BMPs including BMP-2, BMP-6, and BMP-7
in ectopic bone formation and fracture repair (Wozney et
al., 1988; Sampath et al., 1992; Gitelman et al., 1994) and
the roles of BMPs and BMP receptors in embryonic devel-
opment (Dudley et al., 1995; Luo et al., 1995; Mishina et
al., 1995; Winnier et al., 1995; Zhang and Bradley, 1996)
have been well characterized, but the physiological roles of
BMPs and BMP receptor signaling in normal bone forma-
tion in postnatal life are still poorly understood.
Previously, we demonstrated that type IB BMP receptors
play an essential role in osteoblast commitment and differ-
entiation (Chen et al., 1998). In the present studies, we es-
tablished a transgenic mouse model and analyzed the func-
tion of BMP receptors in normal bone formation in vivo.
We found that BMP receptor signaling is necessary for nor-
mal bone growth and bone formation in postnatal and adult
mice. The osteoblast differentiation capacity are clearly im-
paired in these transgenic mice but a role for BMP receptor
signaling in osteoblast proliferation and apoptosis cannot be
ruled out from the present studies.
BMPs may stimulate osteoblast differentiation in part by
inducing expression and activation of a transcription factor,
Runx2/Cbfa1. Targeted disruption of Runx2/Cbfa1 reveals
that Runx2/Cbfa1 is an osteoblast-specific transcription fac-
tor. Homozygous Runx2/Cbfa1-deficient mice die soon af-
ter delivery due to inability to breathe, with the most pro-
nounced effect in these homozygous knockout mice being
a complete lack of both endochondral and intramembra-
nous ossification (Komori et al., 1997; Otto et al., 1997).
In transgenic mice overexpressing mutant Runx2/Cbfa1
(DNA binding domain) driven by the osteocalcin promoter,
Runx2/Cbfa1 function in osteoblasts is blocked. The rates of
bone formation are reduced 70%, and expression of osteo-
blast marker genes is inhibited in the postnatal animals
(Ducy et al., 1999). This reduction in bone formation is
similar to what we observed in homozygous truncated
BMPR-IB transgenic animals. BMP-7 and BMP-2 induce
Runx2/Cbfa1 expression in vitro (Ducy et al., 1997; Chen
et al., 1998) and inhibition of BMP signaling reduces
Runx2/Cbfa1 expression in vitro and in vivo (Chen et al.,
1998; this study).
Null mutations of BMP receptors have been created to un-
derstand the roles of BMP receptor signaling in embryonic
development and postnatal life. Null mutation of the BMPR-
IA gene is embryonic-lethal. Animals die at embryonic day
9.5 dpc, with defects in mesoderm formation, suggesting that
Figure 8. Impairment of osteoblast differentiation 
in truncated BMPR-IB transgenic mice. (A) von 
Kossa staining of cultures of primary osteoblasts 
isolated from calvariae of wild-type and tg(Col-2.3) 
homozygous mice. The cells were cultured for 10 d 
in the presence and absence of 50 ng/ml BMP-2. 
After incubation, the cells were fixed with 10% 
formalin and stained by von Kossa method. (B) 
mRNA expression of Runx2/Cbfa1 and osteocalcin. 
mRNA was extracted from long bones of 1-mo-old 
wild-type and tg(Col-2.3) mice. Significant reduction 
of mRNA expression of Runx2/Cbfa1 and OC in 
homozygous mice was observed by RT-PCR in 
comparison to their wild-type littermates. 
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BMPR-IA is essential for the mesoderm formation during gas-
trulation (Mishina et al., 1995). In contrast, mice lacking
BMPR-IB are viable but exhibit defects in the interphalangeal
joints (Yi et al., 2000). In these BMPR-IB–deficient mice,
proliferation of prechondrogenic cells and chondrocyte differ-
entiation in the phalangeal region are markedly reduced. In
adult mutant mice, the proximal interphalangeal joint is ab-
sent, and the phalanges are replaced by a single rudimentary
element, whereas the distal phalanges are unaffected. The
lengths of the radius, ulna and tibia are normal, but the
metacarpals/metatarsals are reduced. The appendicular defects
in BMPR-IB–null mutant mice resemble those seen in mice
homozygous for the GDF5
 
bp-j
 
 null allele of the GDF5 locus
(Storm et al., 1994). Because GDF5 has been shown to play
a critical role in cartilage formation (Chang et al., 1994;
Thomas et al., 1996, 1997; Storm and Kingsley, 1999) and
bind to BMPR-IB with high affinity (Nishitoh et al., 1996),
these results suggest that BMPR-IB plays a nonredundant role
in cartilage formation in vivo.
BMP ligands may utilize multiple type I receptors to me-
diate signaling during osteoblast differentiation and bone
formation. This hypothesis is supported by the observations
from BMPR-IB and BMP-7 double mutant mice, in which
severe appendicular skeletal defects were observed in fore-
limbs and hindlimbs with almost completely absent ulnae
and shortened radii (Yi et al., 2000). Because BMP-7 binds
efficiently to both BMPR-IB and ActR-IA, and because
ActR-IA also mediates specifically BMP signaling (Macias-
Silva et al., 1998), it is conceivable that BMPR-IB and
ActR-IA play important synergistic or overlapping roles in
bone formation in vivo.
As mentioned earlier, BMPR-IB–null mutant mice show
no dramatic skeletal changes (Yi et al., 2000), although the
absence of BMPR-IB and BMP-7 ligands leads to synergistic
defects in cartilage and bone during development. It is possi-
ble that in the null mutant mice, BMPR-IB is required dur-
ing early development and the surviving animals compensate
through one of the other type I BMP receptors. In the
present studies, we targeted the mutant dominant-negative
BMPR-IB to the osteoblast lineage using the type I collagen
promoter. In this way, we may have been avoided this possi-
ble complication. The dominant negative approach, we and
others have taken to explore the role of BMP receptors, may
alter several of the BMP pathways, and thus is more complex
than simple knockout of the BMPR-IB gene.
The dominant-negative approach of overexpression of in-
active mutant receptors to block receptor signaling is well es-
tablished in studies of BMP signaling during embryonic de-
velopment and specific functions of BMP signaling in vitro
(Maeno et al., 1994; Suzuki et al., 1994; Kawakami et al.,
1996; Zou and Niswander, 1996; Glinka et al., 1997;
Thomas et al., 1997; Zou et al., 1997; Chen et al., 1998;
Frisch and Wright, 1998; Volk et al., 2000). It has been
shown that the mutant BMP type I receptors bind type II
BMP or activin receptors but fail to mediate signaling due to
a lack of or mutation in the kinase domain of the receptors.
The mutant type I receptors partially or completely block
the interacting type II receptor signaling and the degree of
inhibition depends on the expression levels of the mutant
type I receptors similar to what we have observed in our trans-
genic model. Because BMPR-IB interacts with BMPR-II,
ActR-II and ActR-IIB (Liu et al., 1995; Yamashita et al.,
1995; Onishi et al., 1998), which also interacts with other
type I BMP receptors, it is likely that signaling via other type
I BMP receptors is also affected in our transgenic mice. Nev-
ertheless, our studies clearly show a role for BMP receptor
signaling in bone formation in postnatal animals. TGF-
 
 
 
 in-
duces new bone formation over calvariae in both wild-type
and truncated BMPR-IB transgenic mice, strongly suggest-
ing that the blockage of receptor signaling by truncated
BMPR-IB is restricted to BMP signaling pathway.
An issue in using the type I collagen promoter to drive
the truncated BMPR-IB transgene is that overexpression of
the truncated BMPR-IB reduces Runx2/Cbfa1 expression,
which in turn may inactivate the type I collagen promoter.
This is likely not the case in our studies because: (a) Runx2/
Cbfa1 response elements are not located in the type I col-
lagen enhancer/basal promoter and similar phenotypes were
observed in transgenic mice irrespective of whether the type
I collagen enhancer/basal promoter or the 2.3-kb type I col-
lagen promoter was used to generate the mice; (b) There was
no decrease in the expression of the truncated BMPR-IB
transgene in transgenic mice as the animals aged; and (c) A
persistent decrease in BMD in the transgenic mice at differ-
ent ages was observed up to 12 wk of age. These observa-
tions suggest that transcription of the type I collagen gene is
only partly dependent on Runx2/Cbfa1 activation. In fact,
the osteoblast-specific enhancer region of the type I collagen
promoter has been identified in vitro and in vivo by Rossert
et al. (1996), and no Runx2/Cbfa1 response element was
found in this region (Kern et al., 2001).
In summary, our studies provide in vivo evidence that
BMP receptor signaling is necessary for normal murine post-
natal bone growth and bone formation.
 
Materials and methods
 
Construction of type I collagen promoter–truncated 
BMPR-IB transgenes
 
The type I collagen enhancer/basal promoter (Col-0.7) and 2.3-kb type I
collagen promoter (Col-2.3) were used to drive truncated BMPR-IB expres-
sion in transgenic mice. The type I collagen enhancer/basal promoter con-
tains four copies of the osteoblast-specific enhancer and a basal promoter
of the type I collagen gene. To construct Col1a1(0.7)-trBMPR-IB (tg[Col-
0.7]) transgene, the CMV promoter in pcDNA3 vector was removed by
MfeI/HindIII digestion and replaced by a polylinker containing multiple
cloning sites. The type I collagen minimal promoter and the upstream ma-
trix attachment region was released from pJA-ClacZM vector, obtained
from Dr. Benoit de Crombrugghe (Anderson Cancer Center, Houston, TX)
and then cloned into the ClaI/KpnI sites of the polylinker of the modified
pcDNA3 vector. Truncated BMPR-IB cDNA (kinase domain deletion)
(Chen et al., 1998) was then cloned into the multiple cloning sites of the
modified pcDNA3 vector. To monitor expression of the mutant BMPR-IB,
the HA-epitope was tagged at the C-terminal end of the mutant BMPR-IB.
The transgene was released by AscI/NaeI digestion. To generate the
Col1a1(2.3)-trBMPR-IB (tg[Col-2.3]) transgene, the lacZ reporter gene was
removed from the pJ251 vector, obtained from Dr. Benoit de Crombrugghe,
which contains the 2.3-kb mouse type I collagen promoter, by BamHI
digestion. The truncated BMPR-IB cDNA was cloned into the BamHI site
of the pJ251 vector. The transgene was released by KpnI/NarI digestion.
 
Generation of truncated BMPR-IB transgenic mice
 
The tg(Col-0.7) and the tg(Col-2.3) transgenes were excised from vector se-
quences and purified by agarose gel electrophoresis and binding to Gen-
clean glass beads (BIO101, Inc.). Approximately 1 to 2 
 
 
 
l of a solution of
DNA at a concentration of 2 
 
 
 
g/ml was microinjected into the pronuclei of 
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fertilized one-cell mouse embryos (Hogan et al., 1994). The one-cell em-
bryos were derived from mating of CB6F1 (C57BL/6 
 
 
 
 BALB/c) males and
females obtained from Harlan Sprague Dawley, Inc. The injected embryos
were reimplanted into B6D2F1 (C57BL/6 
 
  
 
DBA/2) pseudopregnant fe-
males. The presence of the transgene in the resulting pups was determined
by preparing genomic DNA from a small piece of tail tissue and assaying
by Southern blot analysis (Meinkoth and Wahl, 1984). Homozygous trans-
genic mice were derived from heterozygous transgenic mice and con-
firmed by mating to CB6F1 nontransgenic mice.
 
RNA analysis
 
Total RNA was isolated from different organs of 1-mo-old homozygous
transgenic mice and from bone tissues (calvariae and long bones) of 1-mo-
old wild-type and transgenic mice using RNAzol B solution (Biotex Lab).
RNA expression was analyzed by RT-PCR as described (Chen et al., 1998).
DNAse I-treated total RNA was reverse transcribed using oligo(dT). cDNA
were amplified using the primers specific for truncated BMPR-IB, osteocal-
cin and Runx2/Cbfa1.
 
Western blot analysis
 
To determine protein expression of the truncated BMPR-IB transgene, the
cell lysates were extracted from calvariae of wild-type and transgenic
mice, mixed with sample buffer, and run on SDS-PAGE gels (Mini-PRO-
TEIN II Ready gels; Bio-Rad Laboratories). The proteins were transblotted
onto a PVDF membrane (Bio-Rad Laboratories) in transblotting buffer (20
mM Tris, 150 mM glycine, 20% methanol, pH 8.0) at 4
 
 
 
C for 1 h. The
membrane was blocked with 5% BSA (Sigma-Aldrich) in TBS for 2 h at
room temperature, and incubated with anti-HA polyclonal antibody (200
mg/ml, 1:200 dilution) in TBS for 2 h at room temperature. Incubation with
horse-radish peroxidase conjugated protein A (Kirkegaard & Perry Lab)
was performed at room temperature for 2 h. The membrane was then
washed five times with TBS containing 0.1% Triton X-100 for 5 min and
twice with TBS. Immunostaining was detected using enhanced chemilumi-
nescence (ECL) system (Amersham Pharmacia Biotech).
 
Alizarin red and Alcian blue staining of embryonic skeleton
 
18.5-dpc embryos from transgenic mice and wild-type littermates were
dissected to remove the skin, muscle, and fat and then preserved in ace-
tone for 1 wk to further remove fat, with daily change of the acetone. Em-
bryos were stained with Alizarin red (0.09%) and Alcian blue (0.05%) in a
solution containing ethanol, glacial acetic acid, and water (67:5:28) for
48 h. After staining, embryos were transferred to 1% potassium hydroxide
for 3 d to dissolve the soft tissue and then rinsed with water. Embryos were
preserved in a solution containing glycerin: 1% potassium hydroxide (8:2)
to remove excess stains (Kaufman, 1992).
 
X-Ray analyses of bone structure and BMD measurements
 
To evaluate changes in bone structure in the transgenic mice, animals
were x-rayed using a Faxitron radiographic inspection unit (Model 8050-
020; Field Emission Corporation, Inc.).
A PIXImus bone densitometer (Lunar Corporation), which utilizes Dual
Energy x-ray Absorptiometry (DEXA) technology, was also used to monitor
changes in BMD in the transgenic mice. The advantage of this type of anal-
ysis is that it is non-invasive and therefore the temporal changes in BMD
were monitored in transgenic and wild-type mice. BMD was monitored in
3 litters of animals from three different lines of transgenic mice at 6, 8, 10,
and 12 wk of age.
 
Histological and histomorphometric analyses
 
Histomorphometric analyses were performed on tibial metaphysis in 1-mo-
old wild-type and transgenic mice. Half of bone samples were decalcified
in 14% EDTA and embedded in paraffin and the sections of bone samples
were stained with H&E and tartrate-resistant acid phosphatase. Histological
changes in trabecular and cortical bones and growth plates were analyzed
and changes in osteoblast and osteoclast numbers were quantitated.
The other half of bone samples were embedded in methylmethacrylate.
The sections of bone samples were used for the measurements of BFR or
stained with von Kossa and Goldner methods to determine the bone vol-
ume and osteoid thickness. The trabecular bone volume was quantitated
in the entire area of the bone marrow cavity 1–3 mm from the growth
plates and expressed as a percentage of tissue volume. Values were ex-
pressed as the mean 
 
 
 
 standard error calculated from at least three non-
consecutive sections per mouse from 10 transgenic mice and 10 age-
matched wild-type mice.
To analyze the changes in BFRs, double fluorescence labeling was per-
formed and analyzed in tibial metaphysis. Tetracycline (15 mg/kg i.p.;
 
Sigma-Aldrich) was administered to 1-mo-old wild-type and transgenic
mice, and this was followed by injection of a calcein label (20 mg/kg i.p.;
Sigma-Aldrich) 4 d later, mice were sacrificed 48 h after the second label
was injected, and bone tissues were removed and fixed in 70% ethanol for
48 h. The specimens were dehydrated through a graded series of ethanol
(70–100%) and embedded in methylmethacrylate without prior decalcifi-
cation. 7-
 
 
 
m sections were cut using a Leica 2165 rotary microtome, and
the unstained sections were viewed using fluorescence microscopy, and
the following dynamic indices of bone formation were measured (Uy et
al., 1997): (a) Labeled bone surface (BS) or mineralizing surface; (b) Min-
eral appositional rate (
 
 
 
m/day) 
 
 
 
 mean distance between two fluorescent
labels divided by the number of days between labels; and (c) BFR/BS, 
 
 
 
m
 
3
 
/
 
 
 
m
 
2
 
/day 
 
 
 
 mineralizing surface 
 
  
 
mineral appositional rate/BS.
 
In vivo periosteal bone formation assay
 
Recombinant BMP-2 and TGF
 
 
 
 were injected subcutaneously over the pa-
rietal bone of the calvariae of transgenic mice and wild-type littermates
that were 1-mo-old (Chen et al., 1997). Mice received either vehicle (20 
 
 
 
l
PBS containing 0.1% BSA) alone or BMP-2 or TGF
 
 
 
 (20 
 
 
 
g/kg/d, daily for
5 d). Mice were sacrificed 14 d after commencing injections and calvarial
bones were removed. The bones were decalcified in 14% EDTA and bis-
sected coronally midway between the coronal and lambdoid sutures. The
samples were dehydrated through graded alcohols and embedded in par-
affin. Transverse sections were cut at 3-
 
 
 
m thickness and stained with an
hematoxylin and eosin stain. Newly formed bone were identified by its
woven structure in contrast to preexisting bone with lamellar structure.
The hematoxylin and eosin–stained slides were viewed by the Nikon E400
microscope that was linked to a color video monitor (Sony model PVM-
14M2MDU Trinitron Color Video Monitor; Sony Corp.) and the images
were captured.
 
Immunofluorescence staining
 
Primary osteoblasts were isolated from the calvariae of 3-d-old wild-type and
transgenic mice and transfected with Flag-Smad1. Cells were serum starved
with 
 
 
 
MEM containing 0.2% FCS for 16 h, and treated with BMP-2 (50 ng/
ml) for 15 min. Cells were washed three times with PBS and fixed with 3.8%
paraformaldehyde-PBS. After 15 min of incubation with 0.1% Triton-PBS,
cells were blocked with 1% BSA-PBS, incubated with anti-Flag antibody
(1:500) for 2 h, and washed six times with 0.1% Triton-PBS, followed by in-
cubation with fluorescein isothiocyanate-conjugated anti–mouse IgG anti-
body (Jackson Immunoresearch Laboratories, Inc.). Cells were extensively
washed with PBS and visualized by fluorescence microscope.
 
DNA transfection and luciferase assay
 
Oligonucleotides containing nine copies of GCCG Smad1 binding ele-
ment (9
 
   
 
SBE) was synthesized and cloned in front of osteocalcin basal
promoter (
 
 
 
155/
 
 
 
1) in pGL3 basic vector (9 
 
  
 
SBE-OC-pGL3). The 9 
 
 
 
SBE-OC-pGL3 reporter construct and 
 
 
 
-gal control plasmid was cotrans-
fected in osteoblasts isolated from the calvariae of 3-d-old wild-type and
transgenic mice using lipofactamine plus reagents (GIBCO BRL). After
transfection, the medium was replaced with fresh medium containing 1%
FCS in the presence and absence of BMP-2 (25–200 ng/ml) (R&D Systems).
After a 48-h incubation, the cells were washed with PBS and lysed with ly-
sis buffer and luciferase activity was measured with luciferase assay re-
agents (Promega) using a Luminometer. The luciferase activity was then
normalized by the 
 
 
 
-gal activity.
 
Mineralized bone matrix formation assay
Primary osteoblasts were isolated from the calvariae of transgenic and
wild-type mice and osteoblast differentiation was monitored using a min-
eralized matrix formation assay as described by Bharagava et al. (1986).
The cells were plated in 24-well culture plates at density of 2   10
4 cells/
well and cultured with   minimal essential medium ( MEM) supple-
mented with 10% FCS. When the cells reached confluency (day 0), the
medium was changed to  MEM containing 5% FCS, 100  g/ml ascorbic
acid and 5 mM  -glycerol phosphate with or without 50 ng/ml of BMP-2.
The cells were incubated for 10 d. The medium was changed every other
day and fresh reagents were added. von Kossa stain of mineralized bone
matrix was performed as follows. The cell cultures were washed with PBS
twice, fixed in phosphate buffered formalin for 10 min, and then washed
with water, and serially dehydrated in 70%, 95%, and 100% ethanol,
twice each and air dried. The plates were rehydrated from 100% to 95% to
80% ethanol to water before staining. The water was removed, a 2% silver
nitrate solution was added, and the plates were exposed to sunlight for 20
min, after which the plates were rinsed with water. 5% sodium thiosulfate
was added for 3 min and the plates were then rinsed with water. The mod-BMP receptor and postnatal bone formation | Zhao et al. 1059
ified van Gieson stain was then used as a counterstain after the von Kossa
stain. The unmineralized collagen matrix can be recognized by the yellow/
red van Gieson stain. The acid fuchsin solution (5 part of 1% acid fuchsin,
95 part of picric acid, and 0.25 part of 12 M HCl) was added for 5 min.
The plates were washed with water, and then 2   95% ethanol and 2  
100% ethanol, and dried for image analysis.
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